drugset / Trial / NCT03140722

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722

Phase 2 Terminated 2 enrolled Akebia Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)

Timeline

Start
2017-05-02
Primary completion
2018-03-21
Completion
2018-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Vadadustat Small molecule Oral
Comparator epoetin alfa Protein / enzyme biologic